Results 181 to 190 of about 121,769 (336)

Evidence for investigating GSK-3 inhibitors as potential therapeutics for severe COVID-19. [PDF]

Biochem Biophys Res Commun, 2022
Ghazanfari D, Courreges MC, Belinski L, Bergmeier SC, McCall KD, Goetz DJ.   +5 more
europepmc   +1 more source

Straight to Phase III: Model‐Informed Approach Speeds Depemokimab Clinical Development in Interleukin‐5‐Driven Diseases

Clinical Pharmacology &Therapeutics, EarlyView.
Straight to Phase III: Model‐informed approach speeds depemokimab clinical development in interleukin‐5‐driven diseases. IL‐5, a key mediator of type 2 inflammation, underlies various diseases, including severe asthma, CRSwNP, EGPA, and HES. Reduction in blood eosinophil count (BEC), a biomarker of IL‐5 activity, is commonly used to evaluate the ...
Chiara Zecchin, Stein Schalkwijk, Isabelle J. Pouliquen, Alienor Berges, Nicholas Bird, Richard Follows, Daren Austin   +6 more
wiley   +1 more source

Rapid Alzheimer‐like phosphorylation of tau by the synergistic actions of non‐proline‐dependent protein kinases and GSK‐3 [PDF]

, 1995
Toolsee J. Singh, Niloufar Haque, Inge Grundke‐Iqbal, Khalid Iqbal   +3 more
openalex   +1 more source

Real‐world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study

ESC Heart Failure, Volume 12, Issue 2, Page 1203-1216, April 2025.
The 366 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) were analyzed regarding their clinical characteristics in the first year after approval of tafamidis 61 mg for ATTR‐CM in Germany. Nearly two‐thirds of the patients were in an advanced disease stage and 64% met the key criteria of the “Transthyretin Amyloidosis ...
Richard J. Nies, Svenja Ney, Ingrid Kindermann, Yvonne Bewarder, Angela Zimmer, Fabian Knebel, Katrin Hahn, Sebastian Spethmann, Peter Luedike, Lars Michel, Tienush Rassaf, Maria Papathanasiou, Stefan Störk, Vladimir Cejka, Amin Polzin, Fabian Voss, Malte Kelm, Bernhard Unsöld, Christine Meindl, Michael Paulus, Ali Yilmaz, Bishwas Chamling, Caroline Morbach, Roman Pfister   +23 more
wiley   +1 more source

Regulation of Autophagy by the Glycogen Synthase Kinase-3 (GSK-3) Signaling Pathway. [PDF]

Int J Mol Sci, 2022
Pan HY, Valapala M.
europepmc   +1 more source

<p>Amine derivatives of furocoumarin induce melanogenesis by activating Akt/GSK-3&beta;/&beta;-catenin signal pathway</p>

, 2019
Deng Zang, Chao Niu, Haji Akber Aisa
openalex   +2 more sources

La pourpre de Méditerranée, une source inattendue d’inhibiteurs de GSK-3 [PDF]

, 2004
Laurent Meijer
openalex   +1 more source

GSK-3 Inhibitor LY2090314 [PDF]

, 2020
openaire   +1 more source

Interpretation of in vitro concentration‐response data for risk assessment and regulatory decision‐making: Report from the 2022 IWGT quantitative analysis expert working group meeting

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Quantitative risk assessments of chemicals are routinely performed using in vivo data from rodents; however, there is growing recognition that non‐animal approaches can be human‐relevant alternatives. There is an urgent need to build confidence in non‐animal alternatives given the international support to reduce the use of animals in toxicity ...
Marc A. Beal, Guangchao Chen, Kerry L. Dearfield, Min Gi, Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Alexandra S. Long, David P. Lovell, Barbara L. Parsons, Stefan Pfuhler, John Wills, Andreas Zeller, George Johnson, Paul A. White   +14 more
wiley   +1 more source

The Actions of Lithium on Glaucoma and Other Senile Neurodegenerative Diseases Through GSK-3 Inhibition: A Narrative Review. [PDF]

Cureus, 2022
Singh A, Kumar T, Velagala VR, Thakre S, Joshi A.   +4 more
europepmc   +1 more source